Retatrutide — commonly referred to as reta in patient communities — is a once-weekly injectable medication developed by Eli Lilly and Company. It works as a triple agonist, simultaneously activating three hormone receptors: GLP-1, GIP, and glucagon. That triple mechanism is what separates it from earlier weight loss medications and has generated considerable attention in both clinical and patient circles.
The foundational evidence for retatrutide weight loss comes from a Phase 2 randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2023 (Jastreboff et al.; NCT04881760). The trial enrolled 338 adults with a BMI of 30 or higher — or 27 or higher with a weight-related condition such as hypertension or dyslipidemia — and tested four doses: 1 mg, 4 mg, 8 mg, and 12 mg, all administered once weekly over 48 weeks. Participants with type 2 diabetes were excluded. All participants received diet and physical activity counseling throughout.
Every active dose significantly outperformed placebo. Participants receiving placebo lost approximately 2.1% of body weight at 48 weeks. Across the active arms, results scaled meaningfully with dose — a pattern that held across BMI categories and both male and female subgroups.
The Phase 2 retatrutide weight loss data at 48 weeks breaks down as follows by dose:
The 12 mg dose represents the primary endpoint result — a 24.2% mean reduction in body weight from baseline at 48 weeks. At 24 weeks (the prespecified primary endpoint timepoint), the 12 mg group had already achieved approximately 17.5% mean weight loss, suggesting that weight reduction was still progressing and had not plateaued by the end of the 48-week treatment period.
Looking at responder thresholds — clinically meaningful cutoffs that show what proportion of patients achieve specific weight loss benchmarks — the data are striking:
Beyond weight, cardiometabolic markers improved substantially. At 24 weeks, the 12 mg dose was associated with a 34.0% reduction in fasting triglycerides and a 17.3% reduction in total cholesterol — changes that carry independent clinical relevance for cardiovascular risk.
Then came the Phase 3 data. In December 2025, Eli Lilly announced results from the TRIUMPH-4 trial — a 68-week Phase 3 study. The 12 mg dose produced a mean weight loss of 28.7%, the highest mean weight reduction ever recorded in a Phase 3 obesity trial. That figure represents a meaningful step beyond what was already seen in Phase 2 and reflects a longer treatment duration and a broader patient population.
Context matters when evaluating any new therapy. The table below places retatrutide Phase 2 and Phase 3 results alongside the benchmark Phase 3 trials for the two most established injectable obesity medications.
| Drug | Mechanism | Trial | Duration | Mean Weight Loss (Highest Dose) |
|---|---|---|---|---|
| Semaglutide 2.4 mg | GLP-1 agonist | STEP-1 | 68 weeks | ~14.9% |
| Tirzepatide 15 mg | GLP-1 / GIP dual agonist | SURMOUNT-1 | 72 weeks | ~20.9% |
| Retatrutide 12 mg (Phase 2) | GLP-1 / GIP / Glucagon triple agonist | Phase 2 RCT | 48 weeks | ~24.2% |
| Retatrutide 12 mg (Phase 3) | GLP-1 / GIP / Glucagon triple agonist | TRIUMPH-4 | 68 weeks | ~28.7% |
The progression from dual agonism (tirzepatide) to triple agonism appears to translate into meaningfully greater weight reduction. The glucagon receptor component, which is unique to retatrutide among approved or near-approval agents, is thought to increase energy expenditure and drive additional fat loss — a mechanism that may explain the additional separation seen in trial results.
Numbers on a page can be abstract. To put the Phase 2 primary endpoint in practical terms: a person starting at 250 pounds who achieves 24.2% weight loss would weigh approximately 189 pounds by week 48. At the 28.7% Phase 3 figure, that same individual would reach roughly 178 pounds. These are not marginal changes — they fall within ranges historically associated only with bariatric surgery.
Many patients pursuing treatment for obesity describe food noise — the persistent, intrusive mental preoccupation with food that makes caloric restriction feel like a continuous act of willpower. The GLP-1 component of retatrutide, like other agents in its class, is thought to substantially reduce this phenomenon. In patient community discussions about reta, reduction in food noise is consistently cited as one of the most meaningful subjective changes reported during treatment.
Quality of life data from the Phase 2 trial, measured using the SF-36v2 instrument, showed improvements across all active dose groups at week 48 — consistent with the expectation that meaningful weight reduction translates to better day-to-day function and well-being.
One important clinical question is whether retatrutide weight loss is maintained over time or whether results plateau or reverse. The Phase 2 data showed that at 48 weeks, weight loss curves at the higher doses had not fully flattened — suggesting continued potential at longer durations. The Phase 3 TRIUMPH-4 trial, at 68 weeks, produced even greater mean weight loss than the shorter Phase 2 period, which supports the view that extended treatment continues to yield benefit.
There are important safety considerations to acknowledge. Gastrointestinal side effects — nausea, diarrhea, and vomiting — were the most common adverse events and were dose-dependent, most pronounced during the titration period. A notable finding at higher doses is dysesthesia (abnormal skin sensations): in the TRIUMPH-4 Phase 3 trial, this was reported in 20.9% of participants on the 12 mg dose versus 0.7% on placebo. In Phase 2, hyperesthesia and dysesthesia occurred in 12.9% of the 12 mg group compared to 1.4% on placebo. This side effect warrants careful discussion between any patient and their treating clinician before initiating therapy.
As of April 2026, retatrutide has not received FDA approval and no New Drug Application has been filed. The Phase 3 TRIUMPH program, sometimes called the triple G era by patient community members, is expected to provide the full regulatory package needed for approval consideration. Peer-reviewed Phase 3 publications remain pending.
For those following the development of retatrutide closely, joining the glp3md waitlist is a way to stay informed as the clinical picture continues to evolve. The waitlist at https://www.glp3md.com is an informational resource — joining does not constitute a promise of treatment, medication access, or a prescription, and retatrutide remains an investigational agent that is not currently FDA-approved for any indication. What the waitlist does offer is a structured way to receive updates on trial progress, regulatory developments, and access information as they become publicly available — so that informed decisions can be made when the time comes.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.